Craig-Hallum Remains a Buy on Actuate Therapeutics, Inc. (ACTU)
Craig-Hallum analyst Albert Lowe maintained a Buy rating on Actuate Therapeutics, Inc. today. The company’s shares closed yesterday at $8.22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lowe covers the Healthcare sector, focusing on stocks such as Actuate Therapeutics, Inc., Neurogene, and Eledon Pharmaceuticals. According to TipRanks, Lowe has an average return of 7.1% and a 50.00% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Actuate Therapeutics, Inc. with a $20.00 average price target.
Based on Actuate Therapeutics, Inc.’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6.32 million. In comparison, last year the company had a GAAP net loss of $8.3 million
Read More on ACTU:
Disclaimer & DisclosureReport an Issue
- Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial
- Actuate Therapeutics files to sell 1.33M shares of common stock for holders
- Promising Clinical Developments and Valuation Support Buy Rating for Actuate Therapeutics
- Actuate Therapeutics announces end of Phase 1 portion of elraglusib study
- Actuate Therapeutics Secures $4.7M in Private Placement
